new glp 1 medication FDA approves Foundayo, an oral GLP-1 alternative to Wegovy and Ozempic A Guide to GLP-1s: Resources
Description
doi: 10.1007/s43440-021-00274-8
2 Weight-loss numbers deliberately withheld Despite the obesity markets obsession with headline percentages, AstraZeneca is not disclosing weight-loss magnitude yet
Half of them had subsequently been treated with either Merck & Co.'s Fosamax, Roche and GlaxoSmithKline's Boniva, Amgen's Prolia, or Eli Lilly's Evista or Forteo
Clinical trials show that Ozempic leads to substantially greater weight reduction, while metformin typically results in more modest weight loss
